The United Kingdom and the United States have hammered out a significant trade agreement that will guarantee no tariffs on British pharmaceutical shipments entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase expenditure on pharmaceuticals through the National Health Service (NHS). This move guarantees that tariffs on these key exports will be held at zero for a period of the next three years.
This development comes after recent statements to significantly raise tariffs on branded drug products, with potential rates floated reaching 100%.
"This deal between the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue equity to American-British medicine commerce," a release declared.
Trade Importance
Medicines constitute one of the Britain's biggest exports to the America, which is easily the largest buyer for leading UK drugmakers.
Trade data reveal that in the one-year period prior to September, the UK shipped drugs worth billions to the US. This figure made up 17.4% of total UK exports in that timeframe.
"This deal safeguards work, boosts investment and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The pact includes several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase total health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments were more than twenty percent.
Industry Background
This agreement follows a long-running row between the sector and the British authorities over drug pricing and approval rates.
This friction were exacerbated by arguments that American consumers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward US facilities.
One official stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
